These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

814 related articles for article (PubMed ID: 20455333)

  • 1. Eltrombopag. Idiopathic thrombocytopenic purpura after treatment failure: romiplostim is a better option.
    Prescrire Int; 2010 Feb; 19(105):15. PubMed ID: 20455333
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Thrombopoietin Receptor Agonists in the Treatment of Chronic Resistant Primary Immune Thrombocytopenia: Efficacy and Safety Data in Real Clinical Practice.
    Ptushkin VV; Vinogradova OY; Pankrashkina MM; Chernikov MV; Arshanskaya EG; Tkachenko NE
    Ter Arkh; 2018 Aug; 90(7):70-76. PubMed ID: 30701925
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Cost-effectiveness of Eltrombopag for the Treatment of Immune Thrombocytopenia in the United States.
    Tremblay G; Dolph M; Roy AN; Said Q; Forsythe A
    Clin Ther; 2020 May; 42(5):860-872.e8. PubMed ID: 32199608
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Thrombopoietin Receptor Agonists: Eltrombopag and Romiplostim for the Treatment of Chronic Immune Thrombocytopenia Purpura.
    Atkinson K
    Clin J Oncol Nurs; 2019 Apr; 23(2):212-216. PubMed ID: 30880797
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Thrombopoietin receptor agonists in refractory immune thrombocytopenia: differential responses to eltrombopag and romiplostim: a case report and possible explanations.
    Aoki T; Harada Y; Matsubara E; Suzuki T; Oyama T; Kasai M; Uchida T; Ogura M
    J Clin Pharm Ther; 2012 Dec; 37(6):729-32. PubMed ID: 22583038
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and efficacy of romiplostim in patients with eltrombopag-resistant or -intolerant immune thrombocytopenia.
    Tsukamoto S; Nakaseko C; Takeuchi M; Kumagai K; Komatsu T; Tanaka H; Hara S; Koizumi M; Imai H; Yokota A; Takeuchi M; Inokuchi K; Matsuura Y; Aotsuka N; Wakita H
    Br J Haematol; 2013 Oct; 163(2):286-9. PubMed ID: 23862773
    [No Abstract]   [Full Text] [Related]  

  • 7. Treatment options for chronic refractory idiopathic thrombocytopenic purpura in adults: focus on romiplostim and eltrombopag.
    Chouhan JD; Herrington JD
    Pharmacotherapy; 2010 Jul; 30(7):666-83. PubMed ID: 20575632
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Successful switching from eltrombopag to romiplostim in a pediatric patient with refractory chronic ITP].
    Mori M; Kato M; Koh K; Hanada R
    Rinsho Ketsueki; 2015 May; 56(5):511-3. PubMed ID: 26062675
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Thrombopoietin-receptor agonists for children with immune thrombocytopenia: a systematic review.
    Zhang J; Liang Y; Ai Y; Xie J; Li Y; Zheng W
    Expert Opin Pharmacother; 2017 Oct; 18(15):1543-1551. PubMed ID: 28845713
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The use of thrombopoietin-receptor agonists (TPO-RAs) in immune thrombocytopenia (ITP): a "real life" retrospective multicenter experience of the Rete Ematologica Pugliese (REP).
    Mazza P; Minoia C; Melpignano A; Polimeno G; Cascavilla N; Di Renzo N; Specchia G
    Ann Hematol; 2016 Jan; 95(2):239-44. PubMed ID: 26596973
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Update on romiplostim and eltrombopag indirect comparison.
    Cooper K; Matcham J; Helme K; Akehurst R
    Int J Technol Assess Health Care; 2014 Jan; 30(1):129-30. PubMed ID: 24485057
    [No Abstract]   [Full Text] [Related]  

  • 12. Romiplostim and eltrombopag for immune thrombocytopenia: methods for indirect comparison.
    Cooper KL; Fitzgerald P; Dillingham K; Helme K; Akehurst R
    Int J Technol Assess Health Care; 2012 Jul; 28(3):249-58. PubMed ID: 22980701
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment patterns and clinical outcomes in patients with chronic immune thrombocytopenia (ITP) switched to eltrombopag or romiplostim.
    Kuter DJ; Macahilig C; Grotzinger KM; Poston SA; Wang PF; Dawson KL; Ward M
    Int J Hematol; 2015 Mar; 101(3):255-63. PubMed ID: 25586660
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment efficacy for adult persistent immune thrombocytopenia: a systematic review and network meta-analysis.
    Puavilai T; Thadanipon K; Rattanasiri S; Ingsathit A; McEvoy M; Attia J; Thakkinstian A
    Br J Haematol; 2020 Feb; 188(3):450-459. PubMed ID: 31423574
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Spotlight on eltrombopag in treatment-refractory chronic primary immune thrombocytopenia.
    Garnock-Jones KP
    BioDrugs; 2011 Dec; 25(6):401-4. PubMed ID: 22050343
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Novel thrombopoietic agents: a review of their use in idiopathic thrombocytopenic purpura.
    Stasi R; Evangelista ML; Amadori S
    Drugs; 2008; 68(7):901-12. PubMed ID: 18457458
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Thrombopoietin mimetics for patients with myelodysplastic syndromes.
    Dodillet H; Kreuzer KA; Monsef I; Skoetz N
    Cochrane Database Syst Rev; 2017 Sep; 9(9):CD009883. PubMed ID: 28962071
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Infection-related transient loss of response and other early side effects in chronic ITP during treatment with thrombopoietin mimetics.
    Meyer O; Salama A
    Onkologie; 2011; 34(1-2):10-3. PubMed ID: 21346379
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Thrombosis during thrombopoietin receptor agonist treatment for immune thrombocytopenia. A French multicentric observational study].
    Weber E; Moulis G; Mahévas M; Guy C; Lioger B; Durieu I; Hunault M; Ramanantsoa M; Royer B; Default A; Pérault-Pochat MC; Moachon L; Bernard N; Bardy G; Jonville-Bera AP; Geniaux H; Godeau B; Cathébras P
    Rev Med Interne; 2017 Mar; 38(3):167-175. PubMed ID: 27793553
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Thrombopoietin receptor agonists for preparing adult patients with immune thrombocytopenia to splenectomy: results of a retrospective, observational GIMEMA study.
    Zaja F; Barcellini W; Cantoni S; Carpenedo M; Caparrotti G; Carrai V; Di Renzo N; Santoro C; Di Nicola M; Veneri D; Simonetti F; Liberati AM; Ferla V; Paoloni F; Crea E; Volpetti S; Tuniz E; Fanin R
    Am J Hematol; 2016 May; 91(5):E293-5. PubMed ID: 26910388
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 41.